ArticleJournal of experimental & clinical cancer research : CR2025

Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair.

Xiaojian Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.